INTRODUCTION
Foveal-macular pattern dystrophies (FMPD) are a group of autosomal dominant disorders that involve degeneration of the retinal pigment epithelium (RPE). In the presence of choroidal neovascularization (CNV) these macular patterns are often confused with age-related macular degeneration (AMD) (1) . In 2007 a case was reported in using intravitreal bevacizumab which yielded only visual acuity stabilization (2) . We report the first case of FMPD in which visual acuity and morphologic disease improved after treatment with intravitreal ranibizumab.
CASE REPORT
A 59-year-old Caucasian woman with fundus changes in her right eye was referred to our clinic for evaluation of AMD. Ocular history included macular photocoagulation for presumed AMD in her left eye. Family history was positive for adult-onset foveal-macular pattern dystrophy inherited in an autosomal dominant pattern ( 
DISCUSSION
Foveal-macular pattern dystrophy represents a type of heredodystrophic disorder affecting the pigment epithelium and retina (1) . Treatment of these diseases has always been challenging. Previous therapies for FMPD have included laser photocoagulation, photodynamic therapy, and steroids with only visual acuity stabilization (3) (4) (5) . In the recent years, the anti-angiogenic medications have successfully treated other CNV-related diseases (6) . This is the first report of using ranibizumab to treat FMPD and visual improvement in FMPD after an antiangiogenic medication. Interestingly this patient's visual acuity declined after treatment with bevacizumab, but improved substantially after ranibizumab injection. Of note, laser photocoagulation was performed two months prior to the first ranibizumab injection. Thus, possibly laser and ranibizumab work additively or synergistically to improve vision. It is unlikely that the improvement from months 6-16 was due solely to the laser since vision also improved after the second dose of
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Meeting Eventos Tels.: (11) 3849-8263/3849-0379 Site: http://www.oftalmo.epm.br/simasp2012 ranibizumab given alone ( Figure 1B ). In conclusion, in this patient with FMPD, intravitreal ranibizumab had a therapeutic effect indicated by improved VA and anatomic disease either independent of, or augmented by, prior laser photocoagulation. Further case series are needed to confirm this effect.
